Key Highlights

● Second-quarter revenue was $170.1 million, down from $568.1 million.

● Net income of $80.8 million included a $98.5 million non-cash warrant gain.

● The GAAP operating loss was $19.6 million.

● Stockholders' equity was $354.4 million at June 30, 2026.

When a company reports revenue down 70 percent yet net income of $80.8 million, valuation analysis becomes less simple. Bakkt, Inc. (NYSE:BKKT) did exactly that for the second quarter of 2026, with a large non-cash warrant gain lifting its bottom line while operations still lost money. The gap between accounting equity, operating performance and what the market may be willing to pay is the central valuation question.

Latest Company Context

Bakkt reported second-quarter 2026 results in August. Revenue was $170.1 million, compared with $568.1 million a year earlier. Net income attributable to Bakkt was $80.8 million, or $1.94 per diluted share, but that included a $98.5 million non-cash gain from the change in fair value of Transchem warrants. Excluding such items, the picture was weaker: GAAP operating loss was $19.6 million and adjusted EBITDA was a loss of $11.8 million. Total transacting volume was $168.8 million for the quarter and $410.0 million for the first half. The company held about $50 million in cash and equivalents and reported no long-term debt. Management guided to full-year 2026 transacting volume of about $2.5 billion, assuming activity ramps in the second half.

Key Business and Index Drivers

Balance sheet figures offer one valuation reference. At June 30, 2026, total assets were $403.6 million, liabilities $49.2 million and stockholders' equity $354.4 million, up from $112.8 million at the end of 2025. Class A shares outstanding were 45,059,802, which implies book value of roughly $7.86 per share by simple division; that is a simple calculation, not a company-reported metric. Goodwill of $156.7 million and Transchem warrants carried at fair value of $107.9 million make up a large share of assets, so book value depends heavily on estimates. Bakkt also cites a Strategic Asset Value of about $118.5 million, which it states is not a market or liquidation value. Strategically, the company describes three layers: Bakkt Markets, Bakkt Agent and Bakkt Global, the last holding positions in Transchem in India and Bitcoin Japan.

What Investors Should Watch

Investors may watch whether transacting volume ramps as management expects, since the $2.5 billion full-year target implies a steep increase in the second half after $410.0 million in the first six months. Co-branded card programs and Neobank-as-a-Service offerings are targeted for the fourth quarter, subject to partner, bank, network and regulatory requirements, and delays could weigh on expectations. Fair-value swings in the Transchem warrants may continue to distort reported earnings in either direction. Cash burn is another variable: with adjusted EBITDA negative and about $50 million in cash, funding needs or share issuance could affect per-share value. The share count rose from 25.5 million to 45.1 million over six months, so dilution is worth tracking. The third-quarter report, once scheduled, may provide fresh evidence.

The third-quarter report, when it arrives, will also show whether the second-quarter warrant gain repeats, reverses or stabilizes, and whether regulated infrastructure offerings begin contributing more meaningful revenue. Investors may also compare reported equity with any later market-based measures.

Book Value Built on Estimates

Bakkt's valuation case rests on a balance sheet inflated by fair-value accounting, a debt-free but modest cash position and an operating business that is still loss-making. Whether the market prices the company near book value, the stated strategic asset value or something else may depend on execution in the second half.